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Purpose: To develop a proniosomal carrier system of curcumin for transdermal delivery. 
Methods: Proniosomes of curcumin were prepared by encapsulation of the drug in a mixture of Span 
80, cholesterol and diethyl ether by ether injection method, and then investigated as a transdermal drug 
delivery system (TDDS). The formulated systems were characterized for size, drug entrapment, angle of 
repose, hydration rate and vesicular stability under various storage conditions. In vitro release studies 
were performed using albino rat skin. 
Results: The method used for preparing proniosome resulted in an encapsulation yield of 82.3 – 86.8%. 
Scanning electron microscopy analysis showed that the surface of the particles was smooth. Stability 
data following storage under different conditions showed that the drug content of the proniosomes 
varied from 99.5% under refrigerated condition to 99.2 and 93% at room and elevated temperatures, 
respectively. One of the formulations (PG1) showed prolonged in vitro drug release of 61.8% over a 
period of 24 h.  
Conclusion: It is evident from this study that proniosomes are very stable and promising prolonged 
delivery system for curcumin.   
 
 


















*Corresponding author:  Email: kapil5november@gmail.com; Tel: +91-9997722274
Kumar and Rai  
Trop J Pharm Res, December 2011;10 (6):  698 
INTRODUCTION 
 
Niosomes or nonionic surfactant vesicles are 
microscopic lamellar structures formed on 
admixtures of nonionic surfactant of the alkyl 
or dialkyl polyglycerol ether class and 
cholesterol with subsequent hydration in 
aqueous media [1]. Since the structure of the 
niosome accommodate hydrophilic, lipophilic 
as well as ampiphilic drug moieties, they can 
be used as delivery device for various drugs 
[2]. Proniosome gel is an intermediate state 
of formation of niosome. The niosomes can 
be prepared from the proniosomes by adding 
the aqueous phase with the drug to the 
proniosomes with brief agitation at a 
temperature above the mean transition 
temperature of the surfactant [3]. Proniosome 
possess different advantages over niosome  
i.e. it is not susceptible to instability problems 
like aggregation, fusion, leaking and 
hydrolysis of encapsulated drugs which limits 
the shelf life of the dispersion[4]. 
 
Curcuminoids are oleoresins, derived from 
the ethanolic extraction of turmeric. They are 
primarily responsible for the yellow coloration 
as well as biological activity. Earlier studies 
have shown that curcumin has a wide range 
of therapeutic effects such as anti-
inflammatory [5] , antibacterial [6], antifungal 
[7], anticancer [8]  antispasmodic [9], 
antioxidant [10], antiamoebic [11] , anti HIV 
[12], antidiabetic [13] , antifertility [14]   etc. It 
is reported to be very safe with a toxicity 
profile of 8 g/day. Studies on the 
pharmacokinetics of curcumin indicates its 
poor solubility in acid medium and 
consequently very low absorption from the 
GIT. Furthermore, there is extensive systemic 
metabolism hence its delivery problems and 
lack of clinical success [15]. This ultimately 
leads to poor bioavailability by oral 
administration. Curcumin is already in use by 
topical and oral administration. By the means 
of transdermal drug delivery system all these 
can be avoided and therapeutic efficacy of 
curcumin can be improved. In this present 
study, proniosomal gel of curcumin have 





Curcumin was obtained as the gift from Krish 
Enterprise, Mumbai, India. Span 80 was 
purchased from CDH, Delhi. All other 
chemicals used were of analytical grade. 
 
Ether injection process 
 
Proniosomes containing curcumin of 1:1 ratio 
(PG4) were prepared by dissolving 
cholesterol (50 mg) and   Span 80 (50 mg) in 
2 ml diethyl ether and the solution was 
injected slowly (0.25 ml/min) into a beaker 
containing 200 mg curcumin in 10 ml 
phosphate buffer (pH 7.4). The temperature 
was maintained at 40 – 60 
0
C during the 
injection. The differences in temperature 
between the phases caused rapid 
vaporization of the ether resulting in 
spontaneous vesiculation [16,17]. Three 
other formulations were similarly prepared 
using cholesterol and Span 80 in the ratios 
1:2, 1:3 and 1:4 (see Table 1)  
 












PG1 50 200 1:4 
PG2 50 150 1:3 
PG3 50 100 1:2 
PG4 50 50 1:1 
Each formulation contained diethyl ether (2 ml), drug (50 
mg) 
 
Vesicle size determination 
 
An optical microscope (model) with a 
calibrated eyepiece micrometer was used. 
The diameter of the particles appearing under 
the field of view were measured until about 
200 niosomes were measured individually, 
and their size range and mean diameter were 
calculated 
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Drug content 
 
Proniosomes formulation equivalent to 40 mg 
of curcumin was taken into a standard 
volumetric flask. They were lysed with 100 ml 
of propane-1-ol by shaking and 1 ml of the 
mixture subsequently diluted with phosphate 
buffer (pH 7.4). The absorbance was 
measured spectrophotometrically at 254 nm 
and drug content calculated from the 
calibration curve of curcumin in phosphate 
buffer (pH 7.4).  
 
Scanning electron microscopy (SEM) 
studies 
 
Pure drug and selected formulations were 
sputtered coated using pelco gold palladium 
coaters. The surface morphology of the 
layered sample was examined using SEM. 
The samples were placed in an evacuated 
chamber and scanned in a controlled pattern 
by an electron beam. Interaction of the 
electron beam with the specimen produces a 
variety of physical phenomenon which when 
detected, are used to form images and 
provides information about the specimens. 
[18] 
 
Drug entrapment efficiency of niosomes 
 
Entrapment efficiency of niosomes was 
determined by exhaustive dialysis method. 
The measured quantity of niosomal 
suspension was taken into a dialysis tube to 
which osmotic cellulose membrane was 
securely attached on one side. The dialysis 
tube was suspended in 100ml phosphate 
buffer (pH 7.4), which was stirred on a 
magnetic stirrer. The unentrapped drug was 
separated from the niosomal suspension into 
the medium through osmosis cellulose 
membrane. At every hour entire medium 
(100ml) was replaced with fresh medium (for 
about 9-12 hrs) till the absorbance reached a 
constant reading indicating no drug is 
available in unentrapped form. The niosomal 
suspension in the dialysis tube was further 
lysed with propane-1-ol and estimated the 
entrapped drug by UV spectrophotometric 
method at 254 nm. Entrapment efficiency (E) 
was calculated using Eq 1 [19]. 
 
E (% ) = 100(TD – DD)/TD ……………. (1) 
where TD is total drug and DD is diffused 
drug 
 
Measurement of angle of repose 
 
Angle of repose of dry proniosome of 
curcumin powder was measured by funnel 
method [20].. Proniosomes powder was 
poured into a funnel which was fixed at a 
position so that the 12 mm outlet orifice of the 
funnel is 5cm above a surface. The powder 
flows down from the funnel to form a cone on 
the surface. Angle of repose was then 
calculated by measuring the height of the 
cone and the diameter of its base  
 
Rate of hydration (Spontaneity) 
 
Spontaneity of niosomes formation is 
described as the number of niosomes formed 
after hydration of proniosomes for 15 min. 
Proniosomes were transferred to the bottom 
of a small stoppered glass tube and spread 
uniformly. One ml saline (0.154 M NaCl) was 
added carefully without agitation and the 
solution kept for about 15-20 min after which 
a drop of the aqueous layer was withdrawn 
and placed on Neubaur’s chamber. The 
number of niosomes formed from 




The ability of vesicles to retain the drug (Drug 
Retention Behaviour) was assessed by 
keeping the proniosomal gel at three different 
temperature conditions, i.e., refrigeration (4 – 
8 
0
C), room (25 ± 2 
0
C) and oven (45 ± 2 
0
C). 
Throughout the study, proniosomal 
formulations were stored in aluminium foil-
sealed glass vials. The samples were 
withdrawn at different time intervals over a 
period of one month and drug leakage from 
the formulations was studied by determining 
drug content after storage for one month [21]. 
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In vitro skin permeation study  
 
The in vitro rat skin permeation study was 
carried out as per the guidelines compiled by 
the Committee for the Purpose of Control and 
Supervision of Experiments on Animal 
(CPCSEA), Ministry of Culture, Government 
of India and all the study protocols were 
approved by the local institutional Animal 
Ethics Committee PSIT, Kanpur, India. Also 
an international protocol for conducting 
experiments on animals were followed [22]. 
The abdominal hair of albino rats (wistar 
strain), weighing 200 ± 20 g, was shaved 
using a hand razor. Care was taken not to 
damage the skin surface. The rats were 
sacrificed by administration of excess 
chloroform inhalation and the abdominal skin 
of the rats were separated. The skin was 
stored at −20°C and used within three days 
for the permeation study. It has been 
reported that storage in the refrigerator 
reduces the metabolic activity of the skin. 
Before the permeation study, the skin was 
hydrated in phosphate buffer pH 7.4 
(containing 0.02% sodium azide as a 
preservative) at 4°C over night and the 
adipose tissue layer of the skin was removed 
by rubbing with a cotton swab. 
 
The permeation of drug from proniosomal gel 
formulations was determined by using Franz 
diffusion cell. The excised rat skin was 
mounted on the receptor compartment with 
the stratum corneum side facing upwards into 
the donor compartment. The donor 
compartment was filled with the proniosomal 
gel formulation. Phosphate buffer (15 ml, pH 
7.4) containing 10% PEG was used as 
receptor medium to maintain a sink condition. 
The available diffusion area of the cell was 
3.14 cm
2
. The receptor compartment was 
maintained at 37 ± 1
0
C, with a magnetic 
stirring at 600 rpm. The samples from the 
receptor compartment were withdrawn at 
predetermined time intervals and immediately 
replaced by an equal volume of fresh buffer 
solution. The samples withdrawn from the 
receptor compartment were then analyzed by 
using UV spectrophotometer at 254 nm. 
Statistical analysis 
 
To ascertain drug release mechanism and 
release rate, the data were model fitted to 
various release models - zero order (Eq 2), 
Higuchi (Eq 3) and Korsmeyer-Peppas (Eq 4) 
- using PCP Disso V3.0 dissolution software 
[23,24]. 
 
Release rate = k ……………………… (2) 
 






  …………………………(4) 
 





The low cost, greater stability and resultant 
ease of storage of nonionic surfactant 
vesicles have lead to the exploitation of these 
vesicles as alternatives to phospholipids 
vesicles for the enhancement of dermal 
and/or transdermal bioavailability of drugs 
and substances [25].  
 
SEM (Fig 1) shows that the niosomes 
prepared by ether injection method were 
small in size, unilamellar and spherical in 
shape with a smooth surface. 
 
    
 
 
Figure 1: SEM of (a) pure curcumin and (b) 
formulation PG1 proniosomes 
 
The results of the characterization of the 
curcumin proniosome formulations are shown 
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size (µm, ±SD 












PG1 82.30±0.48 3.84±0.35 36.22±0.43 89±0.42 11.19±0.35 
PG2 83.40±0.76 4.66±0.35 37
o
.22±0.18 85±0.20 15.25±0.58 
PG3 85.20±0.59 4.25±0.35 34
o
.22±0.23 82±0.83 14.54±0.9 
PG4 86.80±0.62 4.32±0.35 33
o
.22±0.06 84±0.55 16.58±0.75 
 
The proniosomes were in the size range 3.84 
- 4.66 µm. Entrapment efficiency was 82.3 % 
for PG1whereas it was 83.4, 85.2%, and 
86.8, for formulations PG2, PG3 and PG4, 
respectively. Angle of repose of the 
formulation was between 33.2 and 36.2
0
. 
Drug content was highest in formulation PG1 
containing (89 %). Rate of spontaneity was 
between 11.19 and 16.58. Stability data for 
formulation PG4 showed that drug content, 
after storage under various temperature 
conditions was 99.5 % (refrigerated 
condition), 99.2 % (room temperature) and 


























Figure 2: Stability of formulation PG4 under 
different conditions 
 
Maximum in vitro skin release in 24 h was 
shown by formulation PG4 (78.5 %) and 






























Figure 3: Cumulative curcumin permeation 
through rat abdominal skin from different curcumin 
niosome formulations (Key: ▲= PG1; ■ PG2; ∆ = 
PG3; □ = PG4) 
 
Kinetic parameters determined are shown in 
Table 3.   
 
To ascertain drug release mechanism and 
release rate, the release data were fittedinto 
release models using PCP Disso V3.0 
dissolution software. The models selected 





The objective in developing proniosomes was 
to devise a method of producing a nonionic 
surfactant based dosage form at the point of  
 
Table 3: Drug release kinetic parameters for the formulations 
 
Zero order Higuchi Korsmeyer-Peppas Formulation 
R K R K Slope (n) R K 
PG1 0.8461 1.2355 0.9825 10.0458 0.7562 0.9752 5.0038 
PG2 0.8124 1.0832 0.9755 8.8554 0.6658 0.9521 5.7985 
PG3 0.9052 1.3568 0.9935 10.1652 0.6521 0.9842 4.8856 
PG4 0.9121 1.4881 0.9928 10.1045 0.6843 0.9621 6.2541 
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use to avoid problems of physical and 
chemical instability found in storage of some 
surfactant-based dosage forms. By creating a 
dry formulation, issues related to hydrolysis 
of the active ingredient or surfactants are 
avoided.  
 
Curcumin is lipid soluble so dissolved in 
chloroform and dispersed uniformly 
throughout the composition. From the above 
study it was observed that as the cholesterol 
content in the vesicles increased, the 
incorporation of the drug in the vesicles also 
increased. Cholesterol is the known to 
increase the rigidity of the proniosomal 
membrane. 
 
The order of encapsulation efficiency 
increases when the concentration of span-80 
was increased. In all the niosomes prepared 
with spans, as the concentration of surfactant 
increased drug entrapment efficiency 
increased. The encapsulation efficiency of 
niosomes is governed by the ability of 
formulation to retain drug molecules in the 
aqueous core or in the bilayer membrane of 
the vesicles. Cholesterol improves the fluidity 
of the bilayer membrane and improves the 
stability of bilayer membrane in the presence 
of biological fluids such as blood/plasma. 
This characteristic of cholesterol decreasing 
leakage of bilayer structure and producing 
surface smoothness diminish at higher 
proportions as it imparts crystallinity to the 
bilayer  
 
The amount of drug retained within the 
vesicles under defined conditions ultimately 
governs the shelf life of the drug. The results 
showed that proniosomal gel formulation was 
quite stable at refrigeration and room 
temperatures as not much leakage of drug 
was found at these temperatures (Figure 2). 
Percent drug retained at 45
0
C might have 
decreased due to the melting of the 
surfactant and lipid present in the formulation. 
Therefore, the proniosomal gel formulations 
can be stored at either refrigeration or room 
temperature. In vitro drug release studies 
(figure 3) indicate that in formulation PG1, 
76% of drug was released after 24 hours 
while PG3 and PG4 had lesser drug release 
after 24 hours. This showed that cholesterol 
formed a film around the vesicles and 
increased the micro viscosity of the bi-layer. 
The thickness of the film depends upon the 
concentration of cholesterol. Hence, inclusion 
of cholesterol improved drug retention time 
and thus reduced permeability. The value of 
n in Korsmeyer-Peppas model is less than 1, 
indicating Fickian diffusion and anomalous 
transport. 
 
It is necessary to improve the bioavailability 
of curcumin in order to fully utilize the 
potential of this agent, and therefore a 
growing number of research groups are 
working on this aim. The study conducted by 
Li et al [24] investigated the effect of 
liposomal curcumin on pancreatic carcinoma 
cells and suppression of KF - kB activity [26]. 
The incorporated curcumin in liposome’s 
showed a dose related increase in apoptosis 
of carcinoma cells and suppression of NF- B 
activity. The study conducted by Kunwar et al 
compared the cellular uptake of liposomal 
and albumin-loaded curcumin by the 
splenetic lymphocytes and EL4 lymphoma 




Proniosomal systems of curcumin made with 
Span 80 exhibited good physicochemical and 
release properties and can easily be 
prepared. Formulations prepared using Span 
80 with cholesterol showed promising results. 
Proniosomes may be a promising carrier for 
curcumin and other drugs, especially due to 
their simple production and facile scale up. It 
is recommended that proniosomal 
formulations should be kept refrigerated to 
achieve best stability. The in-vitro permeation 
of curcumin from proniosomes of various 
compositions and types of nonionic 
surfactants have been studied and evaluated. 
However, in-vivo studies are required to 
prove their actual utility as vehicles for 
transdermal drug delivery. 
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